Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
Dow
Baxter
Colorcon

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201922

See Plans and Pricing

« Back to Dashboard

NDA 201922 describes XIMINO, which is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the XIMINO profile page.

The generic ingredient in XIMINO is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Summary for 201922
Tradename:XIMINO
Applicant:Sun Pharm Inds Inc
Ingredient:minocycline hydrochloride
Patents:6
Formulation / Manufacturing:see details
Pharmacology for NDA: 201922
Medical Subject Heading (MeSH) Categories for 201922
Suppliers and Packaging for NDA: 201922
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Sun Pharmaceutical Industries, Inc 10631-330 10631-330-05 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-330-05)
XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Sun Pharmaceutical Industries, Inc 10631-330 10631-330-30 30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-330-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 11, 2012TE:RLD:No
Patent:  Start TrialPatent Expiration:Apr 2, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:  Start TrialPatent Expiration:Apr 2, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jun 24, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE

Expired US Patents for NDA 201922

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Dow
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.